Spero Therapeutics's total assets for Q1 2026 were $59.02M, a decrease of -14.36% from the previous quarter. SPRO total liabilities were $6.09M for the fiscal quarter, a -38.50% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.